#SFHS2609112AOrder of April 10, 2026, Amending the List of Pharmaceutical Specialties Approved for Use by Public Institutions and Various Public Services
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the list of approved pharmaceutical drugs for public institutions in France. It specifically adds a drug called Tuzulby, in its various dosages, for treating ADHD in children and adolescents aged 6 to 17, when other corrective measures are inadequate.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Tuzulby to the approved list of pharmaceutical drugs.
- Specifies use for ADHD treatment in children and adolescents aged 6 to 17.
- Applicable when other corrective measures are ineffective.
Obligations
What this law requires
Update the official list of approved pharmaceutical specialties for public institutions and services to include Tuzulby 20 mg, 30 mg, and 40 mg (methylphenidate hydrochloride) in extended-release chewable tablet form
Limit reimbursement coverage for Tuzulby to treatment of ADHD (attention deficit disorder with or without hyperactivity) in children and adolescents aged 6 to 17 years only when corrective measures alone are insufficient
Restrict dispensing of Tuzulby to the three approved dosages: 20 mg, 30 mg, and 40 mg in the specified extended-release chewable tablet formulation manufactured by NEURAXPHARM FRANCE
Publish this amended order in the Journal officiel de la République française (Official Journal of the French Republic)
Ensure Tuzulby prescriptions for public institution patients include verification that the patient is aged 6 to 17 years and that corrective measures alone have proven insufficient